{"id":13384,"date":"2011-09-17T16:17:58","date_gmt":"2011-09-17T20:17:58","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=13384"},"modified":"2012-02-04T23:09:21","modified_gmt":"2012-02-05T04:09:21","slug":"racketeer-influenced-and-corrupt-organizations","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2011\/09\/17\/racketeer-influenced-and-corrupt-organizations\/","title":{"rendered":"racketeer influenced and corrupt organizations…"},"content":{"rendered":"\n

In a recent post, I referenced one of Dr. Nemeroff’s review articles, guessing that it was ghostwritten during Janssen’s mid-decade literature Blitzkrieg for Risperdal. As it turns out, this was just one boxcar on a very long train.<\/em><\/p>\n

\n

December 2004<\/font><\/strong>:<\/h1>\n
Charles Nemeroff [Emory], Mark Rapaport [Cedars-Sinai], and six Janssen authors presented this Risperdal augmentation in depression study in a poster session at the ACNP 2004 Meeting<\/em>, concluding:<\/div>\n
    \n
    Risperidone augmentation resulted in symptomatic remission in a substantial number of patients with chronic resistant depression who were nonresponsive to standard antidepressant therapy. Time to relapse in these remitted patients was similar with risperidone vs. placebo augmentation. In the population of fully nonresponsive patients, relapse was significantly delayed with risperidone augmentation.<\/sup><\/div>\n<\/ol>\n

    Fall 2005<\/font><\/strong>:<\/h1>\n
    Dr. Nemeroff’s review article is published in a Supplement to the Journal of Clinical Psychiatry<\/em>. That review contained a report of the study mentioned above:<\/div>\n
    \n
    Use of Atypical Antipsychotics in Refractory Depression and Anxiety<\/font><\/strong><\/u><\/a>
    by Charles B. Nemeroff<\/font><\/strong>, M.D., Ph.D.<\/sup>
    Journal of Clinical Psychiatry<\/font><\/strong> 2005 66[suppl 8]:13–21.
    [    full text on-line<\/font><\/a><\/strong><\/u>]<\/font><\/div>\n

    <\/p>\n

    Treatment options for bipolar depression and treatment-resistant unipolar depression include augmentation of antidepressant therapy with a nonantidepressant drug, including atypical antipsychotics. Risperidone is effective in combination with fluvoxamine, paroxetine, or citalopram in treatment resistant unipolar depression, with reported remission rates of 61% to 76%. Olanzapine in combination with fluoxetine is safe and effective in patients with bipolar depression and those with fluoxetine-resistant unipolar depression. Ziprasidone and aripiprazole augmentation of various selective serotonin reuptake inhibitors has been reported to be effective in refractory unipolar depression in open-label studies. Data on use of quetiapine or clozapine as augmentation therapy for depression or anxiety are not yet available. Further double-blind, placebo-controlled studies of augmentation of antidepressants with atypical antipsychotics in refractory depression and anxiety are justified based on the available literature.<\/sup><\/div>\n<\/blockquote>\n

    June 2006<\/font><\/strong>:<\/h1>\n
    The study was published on-line in Neuropsychopharmacology<\/em> by Mark Rapaport [Cedars-Sinai], Martin Keller [Brown], Charles Nemeroff [Emory], and nine Janssen employees. Dr. Nemeroff was the editor of the Journal at the time: <\/div>\n
    \n
    Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation<\/font><\/strong><\/u>.<\/a>
    by Rapaport MH<\/font><\/strong>, Gharabawi GM, Canuso CM, Mahmoud RA, Keller MB<\/font><\/strong>, Bossie CA, Turkoz I, Lasser RA, Loescher A, Bouhours P, Dunbar F, and Nemeroff CB<\/font><\/strong><\/sup>
    Neuropsychopharmacology<\/font><\/strong>. 2006 31(11):2505-13.
    [    full text on-line<\/font><\/strong><\/u><\/a>]<\/div>\n

    <\/p>\n

    Erratum<\/font><\/strong> in<\/div>\n